Related Experiment Videos
COMT inhibition with nitecapone does not affect the tyramine pressor response
1Research Center, Orion Pharmaceutica, Espoo, Finland.
British Journal of Clinical Pharmacology
|July 1, 1991
Summary
Nitecapone, a COMT inhibitor, does not enhance the blood pressure effects of tyramine, which releases catecholamines. This study found no potentiation of hemodynamic responses in healthy volunteers.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Catecholamine-O-methyltransferase (COMT) inhibitors are used in various therapeutic areas.
- Nitecapone is a novel selective COMT inhibitor with known gastroprotective effects.
- The potential interaction between nitecapone and catecholamine release requires investigation.
Purpose of the Study:
- To evaluate whether nitecapone potentiates the hemodynamic effects of tyramine-induced catecholamine release.
- To assess the impact of nitecapone on systolic blood pressure response to tyramine in healthy individuals.
Main Methods:
- A placebo-controlled study involving 11 healthy male volunteers.
- Intravenous administration of tyramine in increasing doses.
- Measurement of systolic blood pressure response before and after oral nitecapone (25 mg and 100 mg).
Main Results:
- The tyramine 'pressor dose' (dose required to increase systolic blood pressure by 30 mm Hg) was similar across all conditions (no medication, 25 mg nitecapone, 100 mg nitecapone).
- No significant differences were observed in the systolic blood pressure response over time between the treatment groups.
- Nitecapone did not potentiate the pressor response to tyramine.
Conclusions:
- COMT inhibition by nitecapone does not potentiate the hemodynamic effects of tyramine-induced catecholamine release.
- Nitecapone appears safe regarding acute cardiovascular responses to catecholamine surges in healthy individuals.